Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Grako KA;Grako KA; Stallcup WB
- Source:
Experimental cell research [Exp Cell Res] 1995 Nov; Vol. 221 (1), pp. 231-40.
- Publication Type:
Journal Article; Research Support, U.S. Gov't, P.H.S.
- Language:
English
- Additional Information
- Source:
Publisher: Academic Press Country of Publication: United States NLM ID: 0373226 Publication Model: Print Cited Medium: Print ISSN: 0014-4827 (Print) Linking ISSN: 00144827 NLM ISO Abbreviation: Exp Cell Res Subsets: MEDLINE
- Publication Information:
Publication: Orlando Fl : Academic Press
Original Publication: New York, Academic Press.
- Subject Terms:
- Abstract:
Through immunohistochemical studies we have identified the cell-surface proteoglycan, NG2, on blood vessels throughout the rat embryo. The particular cell type expressing this chondroitin sulfate proteoglycan, however, is dependent upon tissue location. Microvessels within the rat CNS express NG2 on endothelial cells, while in blood vessels outside the CNS, NG2 is found on smooth muscle cells. To analyze what role NG2 might play in these blood vessels, an enzymatic dissociation protocol was used to establish primary cultures of vascular smooth muscle cells from Postnatal Day 3 rat aorta. In this study we demonstrate the involvement of NG2 in the mitogenic and chemoattractant responses of smooth muscle cells to PDGF. In assays measuring either DNA synthesis or cell migration, treatment of smooth muscle cells with anti-NG2 immunoglobulins decreased their responses to PDGF-AA but had no effect upon their ability to react to PDGF-BB. These results support a role for NG2 in potentiating signaling through the alpha PDGF receptor in vascular smooth muscle cells. The presence of the proteoglycan on a large subpopulation of these cells could provide an enhanced response to the growth factor in times of active normal growth or in pathological conditions, such as arterial injury or atherosclerosis.
- Grant Information:
R01 NS 21990 United States NS NINDS NIH HHS
- Accession Number:
0 (Antigens)
0 (Mitogens)
0 (Platelet-Derived Growth Factor)
0 (Proteoglycans)
0 (chondroitin sulfate proteoglycan 4)
EC 2.7.10.1 (Receptors, Platelet-Derived Growth Factor)
G34N38R2N1 (Bromodeoxyuridine)
- Publication Date:
Date Created: 19951101 Date Completed: 19951214 Latest Revision: 20131121
- Publication Date:
20231215
- Accession Number:
10.1006/excr.1995.1371
- Accession Number:
7589250
No Comments.